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Chapter 9
The role of nitric oxide in the pathophysiology of
intimal hyperplasia
Sadaf S. Ahanchi, MD, Nick D. Tsihlis, PhD, and Melina R. Kibbe, MD, Chicago, Ill
Since its discovery, nitric oxide (NO) has emerged as a biologically important molecule and was even named Molecule of
the Year by Science magazine in 1992. Specific to our interests, NO has been implicated in the regulation of vascular
pathology. This review begins with a summary of the molecular biology of NO, from its discovery to the mechanisms of
endogenous production. Next, we turn our attention to describing the arterial injury response of neointimal hyperplasia,
and we review the role of NO in the pathophysiology of neointimal hyperplasia. Finally, we review the literature regarding
NO-based therapies. This includes the development of inhalational-based NO therapies, systemically administered
L-arginine and NO donors, NO synthase gene therapy, locally applied NO donors, and NO-releasing prosthetic
materials. By reviewing the current literature, we emphasize the tremendous clinical potential that NO-based therapies
can have on the development of neointimal hyperplasia. ( J Vasc Surg 2007;45:64A-73A.)NITRIC OXIDE: THE BASICS
Since its discovery 20 years ago, nitric oxide (NO) has
emerged as an important signaling molecule in a myriad of
pathways, including the nervous, immune, and cardiovas-
cular systems. It was even named Molecule of the Year by
Science magazine in 1992. This review focuses on the
actions of NO in the vasculature and, more specifically, as a
treatment to prevent the development of neointimal hyper-
plasia that arises after vascular interventions.
Nitric oxide was initially discovered in an attempt to
reconcile the apparent conflict in the actions of acetylcho-
line in vivo and in vitro. Although acetylcholine is normally
a potent vasodilator in vivo, during preparations of vessels
for in vitro studies, denuding of the endothelial layer by
accidental rubbing caused loss of responsiveness to acetyl-
choline, yielding conflicting results.1 It was suspected that
the endothelial cells were releasing a substance that aided in
acetylcholine-induced vasodilation and that this substance
was subsequently lost from the denuded in vitro prepara-
tions. This molecule was termed endothelial-derived relax-
ation factor. Eventually, NO was identified as the endothelial-
derived relaxation factor responsible formediatingvasodilation in
response to acetylcholine, and it was the loss of the endothe-
lial-derivedNO that was confounding the in vitro studies of
acetylcholine activity.2
Once it was determined that NO existed in cells, re-
searchers endeavored to discover how it was produced and
regulated. The mechanism of synthesis was shortly discov-
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64Aered to proceed through oxidation of one of the amidine
nitrogens of L-arginine, yielding NO and L-citrulline (Fig 1).3
Upon its synthesis, NO was shown to be a potent stimula-
tor of guanylate cyclase to form cyclic guanylate mono-
phosphate (cGMP) and cause relaxation of vascular smooth
muscle cells (VSMC).4,5 These investigations into the role
of NO as a signaling molecule in the cardiovascular system
earned Drs Robert F. Furchgott, Louis J. Ignarro, and
Ferid Murad a Nobel Prize in Physiology and Medicine in
1998.6-8
While the role of NO in the vasculature was being
determined, focus was also aimed at understanding the
regulation of NO synthesis in the cell. To this end, three
forms of NO synthase (NOS) were discovered by research-
ers: neuronal NOS (nNOS), inducible NOS (iNOS), and
endothelial NOS (eNOS).9 These isoforms are clearly dis-
tinct but share a number of similarities. They all require the
cofactors nicotinamide adenine dinucleotide phosphate hy-
drogen, flavin adenine dinucleotide, flavin mononucle-
otide, and tetrahydrobiopterin to catalyze the enzyme re-
action.9
In general, eNOS and nNOS are constitutively ex-
pressed enzymes, and NO production is predominately
regulated by intracellular calcium fluxes that permit cal-
modulin binding, which activates the enzyme.9 In contrast,
iNOS is transcriptionally regulated and is not normally
produced by most cells.9,10 Typically, iNOS is expressed in
response to cellular stress and generates 100-fold to 1000-
fold more NO than its constitutive counterparts that are
involved in physiologic regulation.10,11
ARTERIAL INJURY RESPONSE:
NEOINTIMAL HYPERPLASIA
Neointimal hyperplasia is an exaggerated healing pro-
cess that occurs in the vessel wall after injury. It is respon-
sible for restenosis, limiting the success of many vascular
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and balloon angioplasty with or without stenting. The
development of neointimal hyperplasia is a complex process
initiated by injury and exposure of the VSMC to circulating
blood elements. The process is further characterized by
platelet aggregation, leukocyte chemotaxis, VSMC prolif-
eration and migration, extracellular matrix (ECM) changes,
and, finally, endothelial cell proliferation.
As mentioned, the initiating event in neointimal hyper-
plasia is endothelial denudation. Disrupting the overlying
layer of endothelium exposes the underlying VSMC to
circulating blood elements, which then activates a cascade
of events culminating in neointimal hyperplasia.12 Rat
common carotid arteries lacking endothelium reliably pro-
duce neointimal hyperplasia. To systematically study this
response, Alexander Clowes, MD, established the rat ca-
rotid artery balloon injury model, which is still consistently
used in the investigation of the pathophysiology of neoin-
timal hyperplasia.12
Within seconds after endothelial loss, platelets aggre-
gate and adhere to the site of injury.13 This was demon-
strated by removal of the endothelium from the carotid
artery of a rat using a balloon catheter, which subsequently
led to the rapid accumulation of platelets on the exposed
subendothelium as measured by scanning electron micros-
copy.13 These platelets remained adhered for 6, 24, and 48
hours and up to 4 and 7 days after injury.13 The platelets
formed a monolayer in most regions and discharged the
contents of their dense granules.14 Among the substances
released were platelet-derived growth factor (PDGF) that
caused VSMC migration and proliferation in the injured
wall.14,15
After platelet aggregation and adherence, leukocyte
chemotaxis occurs. Leukocytes are paramount in the secre-
tion of many cytokines and growth factors that influence
t h e subsequent events in neointimal hyperplasia (Table I).16
One example is macrophages that produce PDGF and
interleukin-1 (IL-1), which both promote VSMC prolifer-
ation and are released in the arterial wall during the repair
Fig 1. Production of nitric oxide (NO) by nitric oxide synthase
(NOS). NADP, nicotinamide adenine dinucleotide phosphate;
FAD, flavin adenine dinucleotide; FMN, flavin mononucleotide;
HEME, hemoglobin; H4B, tetrahydrobiopterin; O2, oxygen;
Ca2, calcium; CaM, calmodulin.process.17,18 The central role of leukocyte chemotaxis isdemonstrated by the novel model for inflammatory neoin-
timal hyperplasia that consists of leukocyte-derived myelo-
peroxidase in the presence of its substrate hydrogen perox-
ide. The infusion of myeloperoxidase (200 nM) and
hydrogen peroxide (1 mM) into an isolated rat common
carotid artery, followed by 1-hour incubation, elicited a
neointimal hyperplasia not seen in the arteries infused with
phosphate buffered saline.19 It was postulated that in this
model, the myeloperoxidase and hydrogen peroxide were
able to induce neointimal hyperplasia without mechanical
injury to the rat common carotid artery by compromising
NO signaling through an as-yet-unknown mechanism.20
In conjunction with leukocyte chemotaxis, VSMC pro-
liferation and migration are the fundamental characteristics
of neointimal hyperplasia. This proliferation is, in part,
initially mediated by the release of basic fibroblast growth
factor (bFGF), which is a potent mitogen for VSMC in
vivo.21 Proliferation begins as early as 24 hours after injury
and continues for several weeks.22 Under the influence of
platelet-derived growth factor (PDGF), VSMC begin mi-
grating to the intima between 1 to 3 days after injury.23
The ECM generally acts as a barrier to VSMC migra-
tion from the media to the intima; however, after injury the
ECM is modified to allow for the movement of cells.
Migration and matrix reconfiguration are associated with
an increase in the expression and activity of matrix-degrading
enzymes. Two examples, plasminogen activator, which ly-
ses clots and activates matrix-degrading enzymes, and ma-
trix metalloproteinase, which degrades collagen and elastin,
are upregulated after injury.24,25
While some elements of the ECM undergo degrada-
Table I. Cellular sources of growth factors and cytokines
involved in the pathogenesis of fibroproliferative
vasculopathies
Growth factors,
cytokines
Cell source
Leukocytes
Monocytes,
macrophages Mast cells
IGF-1 X
PDGF X X
TGF- X
TGF- X X X
VEGF X X X
EGF X
FGF X
TNF- X X X
IL-1 X X X
IL-4 X X
IL-6 X X
IL-8 X X X
IL-10 X X
IL-18 X X X
MCP X X X
IGF, Insulin-like growth factor; PDGF, platelet-derived growth factor; TGF,
transforming growth factor;VEGF, vascular endothelial growth factor; EGF,
epidermal growth factor; FGF, fibroblast growth factor; TNF, tumor necro-
sis factor; IL, interleukin, MCP, macrophage chemoattractant protein.
Adapted from Mitra et al.16tion, other elements seem to be upregulated. After balloon
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transforming growth factor- (TGF-), which correlated
with increased fibronectin, type I collagen, and type III
collagen gene expression.26 Gene transfer of TGF- also
resulted in the production of procollagen, collagen, and
proteoglycans.27
Cells producing certain ECM components may also be
targets for regulation. This is demonstrated by the targeted
reduction of cGMP-dependent protein kinase I expression
in response to injury in proliferating VSMC simultaneously
expressing osteopontin, an ECM protein.28
Finally, to restore the protective barrier of the endothe-
lium disrupted by injury, endothelial proliferation must
occur. Concurrent with VSMC proliferation and migra-
tion, endothelial regeneration begins through stimulation
by bFGF 24 hours of injury.29 This regeneration begins
from the ends of the denuded area and approaches
the center within several weeks, restoring endothelial
continuity.12
EFFECTS OF NITRIC OXIDE ON NEOINTIMAL
HYPERPLASIA
All the aforementioned events lead to the development
of neointimal hyperplasia. The next question is: what is the
role of NO in the formation of neointimal hyperplasia?
Studies conducted with NOS knockout mice and NOS
inhibitors demonstrate the importance of NO in regulating
neointimal hyperplasia. The eNOS knockout mice that
underwent external carotid artery ligation displayed an
impaired vascular remodeling, accompanied with an in-
crease in wall thickness and a hyperplastic response of the
arterial wall.30 Endothelium-derived relaxing factor activ-
ity, as assayed by acetylcholine-induced relaxation, was also
absent in eNOS knockout mice, producing hypertension.31
The eNOS knockout mice have specifically been shown to
have an exacerbated carotid artery ligation-induced expres-
sion of stromal cell-derived factor-1, a molecule involved
in recruitment of circulating VSMC progenitor cells into
the neointima.32 The mice lacking eNOS also demon-
strated an increase in circulating stem cell antigen-1 cells,
Fig 2. Role of nitric oxide (NO) in neointimal hyperpla
(above) elements of the vasculature that ultimately res
vascular smooth muscle cells.which has been shown to be a progenitor to VSMC.32 Thissuggested that constitutive eNOS inhibited stromal cell-
derived factor-1 expression and provided an important
vasculoprotective mechanism for intact endothelium to
limit VSMC proliferation and recruitment in response to
vascular injury.32
Finally, rats that received pharmacologic NOS inhibi-
tion with L-nitro-1-arginine and cyclooxygenase inhibition
with indomethacin synergistically were found to have in-
creased intimal thickening after balloon catheter injury of
the left carotid artery.33 Together, these studies demon-
strate that a primary defect in the NOS/NO pathway
promotes abnormal remodeling and neointimal hyperpla-
sia, and verifies the critical role for endogenous NO in
maintaining a normal vascular environment (Fig 2).
Inhibition of platelet aggregation and adhesion.
Nitric oxide acts through several mechanisms to protect the
vasculature. One of the initial mechanisms is the ability of
NO to prevent platelet aggregation. In 1987, Radomski et
al34 discovered that NO contributed to the nonadhesive
properties of the vascular endothelium by demonstrating
that the adhesion of unstimulated and thrombin-
stimulated platelets washed and labeled with indium-111
was lower in the presence of exogenous NO. After balloon
catheter denudation of the rat carotid artery, Yan et al35
measured iNOS expression, platelet adhesion, and blood
flow. The results showed that upregulation of iNOS in vivo
not only prevented the adherence of platelets to the injured
site but also preserved blood flow.35 Because injury results
in endothelial denudation and loss of eNOS, upregulation
of iNOS represents a protective mechanism against platelet
adherence that compensates for the loss of the endothe-
lium.
Inhibition of leukocyte chemotaxis. After arterial
injury, leukocytes accumulate and produce several growth
factors and cytokines that stimulate VSMC proliferation
and migration. Nitric oxide has been shown to inhibit the
inflammatory infiltration and, hence, inhibit the accumula-
tion of VSMC. This has been verified by disruption of the
NOS/NO pathways. Inhibitors of NO production, NG-
monomethyl-L-arginine (L-NMMA) or NG-nitro-L-
itric oxide works to both stimulate (below) and inhibit
n overall inhibition of neointimal hyperplasia. VSMC,sia. N
ults iarginine methyl ester (L-NAME), when infused into a cat
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emigration as measured by intravital video microscopy.36
In addition, when compared with wild-type mice, iNOS-
deficient mice have a higher number of rolling and adher-
ent leukocytes in postcapillary venules of the cremaster
muscle and the sinusoids as well as postsinusoidal venules of
the hepatic microcirculation in response to an endotoxin
infusion as seen by intravital video microscopy.37 These
results suggest that NO production after iNOS upregula-
tion that follows an injury may function as a homeostatic
regulator of leukocyte recruitment and may play a role in
regulation of vascular inflammation.
Inhibition of vascular smooth muscle cell prolifer-
ation and migration. Early studies demonstrated that
NO modulates VSMC proliferation through a cGMP-
mediated mechanism.38 Further research has revealed some
of the details behind this inhibition. One mechanism is
through the induction of a G0/G1 cell cycle arrest that
prevents cells from entering the synthesis phase of the cell
cycle required for proliferation.39 This was demonstrated
by Sarkar et al39 in the treatment of cultured rat aortic
VSMC with the NO donors S-nitroso-N-acetylpenicillamine
(SNAP) and S-nitrosoglutathione. The introduction of the
NO donors resulted in a 50% reduction in the fraction of
cells in the S and G2M phases and an increase in the G1
fraction, suggesting that NO inhibited entry into S phase
and caused accumulation in G1 phase.39
Subsequently, Ishida et al40 used SNAP-treated VSMC
to demonstrate that NO halted the G1/S transition by a
p21-mediated inhibition of the phosphorylation of the
retinoblastoma protein by cyclin-dependent kinase 2. Gene
transfer of iNOS into VSMC has also demonstrated a
p53-independent and cGMP-independent increase in ex-
pression of p21, a cyclin-dependent kinase inhibitor known
to inhibit cell cycle progression.41 Further verification by
Tanner et al42 demonstrated that NO has been shown to
alter the expression or activity of many cell cycle regulatory
proteins, including cyclin A, cyclin-dependent kinase 2, and
p21.40
Nitric oxide also retards the VSMC migration that, in
addition to VSMC proliferation, plays a key role in neoin-
timal hyperplasia. Dubey et al43 showed that the NO
donors sodium nitroprusside and SNAP inhibited angio-
tensin II–induced rat VSMC migration in vitro, as mea-
sured by a modified Boyden Chamber. Similarly, stimulat-
ing iNOS expression using IL-1 increasedNOproduction
and inhibited angiotensin II–stimulated rat aortic VSMC
migration.43 In fact, many NO donors, including diethyl-
amine NONO-ate (DETA/NO), spermine NONO-ate
(SPER/NO), and S-nitrosoglutathione, all exhibited
concentration-dependent inhibition of both the number of
migrating VSMC and the maximal distance migrated.44
This inhibition was reversible upon removal of the NO
donors.
Stimulation of vascular smooth muscle cell apoptosis.
Apoptosis of VSMChas an important role in the prevention
of neointimal hyperplasia. Although the regulation of
VSMC apoptosis is not fully understood, NO has beenshown to induce apoptosis. Pollman et al45 showed that the
administration of NO donors SNAP or sodium nitroprus-
side to cultured rabbit VSMC caused apoptosis in a dose-
dependent fashion as measured by propidium iodide stain-
ing. Also in 1996, Nishio et al46 exposed rabbit VSMC to
SNAP and showed a dose-dependent increase in apoptosis
by NO as measured by terminal deoxynucleotide trans-
ferase-mediated dUTP biotin nick end-labeling (TUNEL).
They also showed that addition of cGMP inhibitor
KT5823 had no effect on NO-mediated apoptosis, indicat-
ing a cGMP-independent pathway.46
In 1998, a complimentary DNA (cDNA) construct
expressing iNOS was transfected into rat and human
VSMC by lipofection, resulting in expression of the iNOS
protein with full catalytic activity to generate massive NO in
proportion to the cDNA used.47 Overexpression of iNOS
led tomarked inhibition of DNA synthesis and induction of
apoptosis in VSMC as measured by internucleosomal DNA
fragmentation by agarose gel electrophoresis, positive
staining for TUNEL, and the appearance of hypodiploid
cells in flow cytometry analysis.47 In addition, apoptosis
was markedly suppressed when the NOS inhibitor L-
NMMA was administered to the iNOS-transfected VSMC,
further solidifying the role of NO in regulation of apopto-
sis.47
Extracellular matrix changes. As mentioned previ-
ously, the ECM acts as a barrier to VSMC migration from
the media to the intima. Nitric oxide inhibits VSMC mi-
gration in part by regulating matrix metalloproteinase
(MMP) activity, the enzymes responsible for degrading the
basement membrane and the ECM.48 Interestingly, when a
replication-deficient adenovirus containing bovine eNOS
was transfected into cultured rat aortic VSMC, the NO
produced decreased the activity of MMP-2 and MMP-9
while increasing the activity of the tissue inhibitor of
metalloproteinases-2.48 DNA chip studies of L-NAME–
induced hypertensive rat, showed a significant modulation
of 28 known genes at both 15 and 30 days after treat-
ment.49 The functional classification of the genes high-
lighted three major biologic pathways modulated in the
aortic media during L-NAME administration: genes regu-
lating cell proliferation, genes of the NO/cGMP signaling
pathway, and genes involved in ECM remodeling.49
This matrix reconfiguration involves both degradation
and deposition of matrix elements. In grafts treated with
the NO donor SPER/NO, expression of insulin-like
growth factor (IGF), bFGF, thrombospondins, fibronec-
tin, and tenascin was reduced.50 L-arginine, the substrate
for NO production, significantly diminished hyaluronan
synthase expression (one of the two enzymes responsible
for making hyaluronan, a key component of the ECM).51
Another NO donor, DETA/NO, caused cell cycle arrest
associated with overexpression of TGF-1 and an increase
in synthesis of collagen I and III in human coronary
VSMC.52
Conversely, studies have demonstrated inhibition of
collagen levels with NO. In vitro, NO has been demon-
strated to directly inhibit basal type I collagen levels and
nitric
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protein synthesis, and ECM production as measured by cell
counts and enzyme-linked immunosorbent assay.53 Two
additional NO donors, SNAP and sodium nitroprusside,
also inhibited total protein and collagen synthesis within
VSMC.54 Thus, NO produces a complex effect on the
ECM that ultimately creates an environment limiting the
migration of VSMC.
Stimulation of endothelial cell proliferation. Nitric
oxide has been demonstrated to play a dual role in regulat-
ing cells after arterial injury. While NO inhibits VSMC
proliferation, it stimulates endothelial regeneration.55 Ni-
tric oxide appears to trigger capillary endothelial cell
growth and differentiation through cGMP-dependent
gene transcription,56 and is also is a component of the
pathways underlying vascular endothelial growth factor
(VEGF)-activated endothelial cell proliferation.57 Vascular
endothelial growth factor induces the expression of eNOS
and promotes the release of NO through activation of the
MAPK cascade.57 Furthermore, NOS inhibition with L-
NAME blocks angiogenesis induced by VEGF and sub-
stance P in rabbit cornea.58,59 In eNOS-deficient mice, the
angiogenic response to hind limb ischemia was impaired
and could not be overcome by administration of VEGF.60
Of interest was that although VEGF-induced angiogenesis
is mediated by NO, the capillary growth stimulated by
FGF-2 can be both NO-independent and inhibited by
NO.61,62 Although different proposed mechanisms exist,
the end result is the stimulation of endothelial cell prolifer-
Table II. Therapeutic effects of nitric oxide on neointima
Method NO source
%
Inhibitio
Inhalational NO NO 43 
Systemic L-arginine L-arginine 39 
L-arginine 65 
Systemic NO donors Molsidomine 32 
Linsidomine, molsidomine 18 
NO-releasing aspirin 23 
Molsidomine 0 
NOS gene therapy Adenoviral eNOS 70 
Adenoviral eNOS 37 
Adenoviral eNOS 72 
Adenoviral eNOS 28 
Adenoviral iNOS 95 
Adenoviral iNOS 52
Adenoviral iNOS 30 
Adenoviral iNOS 37 
Local NO donors NO-albumin 77 
L-arginine 37 
SPER/NO 41 
SNAP 36 
SPER/NO 73 
SIN-1 46 
NO-releasing prosthetics NO eluting stent 0 
NO eluting stent 32 
NO eluting stent 80 
NO, Nitric oxide; iNOS, inducible nitric oxide synthase; eNOS, endothelial
S-nitroso-N-acetylpenicillamine; SIN-1, 3-morpholino-sydnonimine.ation by NO.Inhibition of endothelial cell apoptosis. In a further
attempt to maintain the integrity of the endothelial layer,
NO also suppresses endothelial cell apoptosis. Using cul-
tured human umbilical vein endothelial cells that had been
subjected to shear stress in the presence of NO, Dimmeler
et al demonstrated that NO prevented apoptosis.63 Simi-
larly, Tzeng et al64 showed that an adenoviral vector over-
expressing iNOS caused an inhibition of lipopolysaccharide-
induced apoptosis in cultured sheep arterial endothelial
cells by reducing caspase-3-like protease activity. In further
support, DeMeester et al65 showed a similar inhibition of
endothelial cell apoptosis by NO in cells cultured from a
porcine model. Taken together, these results suggest that
NO production favors healing of the injured vasculature by
inhibiting further apoptosis in order to rapidly cover the
injured site. Once endothelial cell regeneration is complete,
the stimulus for platelet adherence and leukocyte chemo-
taxis is removed, and the cascade of cytokine and growth
factor release leading to neointimal hyperplasia is abolished.
NITRIC OXIDE-BASED THERAPIES
Given the role of NO in maintaining a normal vascular
environment, many investigators have hypothesized that
replacement of NO at the site of injury would prevent
development of neointimal hyperplasia. Here we attempt
to summarize the gamut of NO-based therapies that have
been investigated to date (Table II).66-87
Inhalational nitric oxide. In 1996, Lee et al exam-
ined the effects of inhalational NO on neointimal hyperpla-
erplasia
pecies Model
Time
period Reference, year
at Balloon angioplasty 2 wk Lee,66 1996
abbit Balloon angioplasty 2 wk McNamara,67 1993
at Balloon angioplasty 2 wk Chen,68 1999
ig Balloon angioplasty 3 wk Groves,69 1995
uman Coronary angioplasty 6 mo Lablanche,70 1997
ouse Balloon angioplasty 3 wk Napoli,71 2001
uman Coronary angioplasty 6 mo Wohrle,72 2003
at Balloon angioplasty 2 wk von der Leyen,73 1995
at Balloon angioplasty 2 wk Chen,74 1998
at Balloon angioplasty 2 wk Janssens,75 1998
ig Coronary angioplasty 3 wk Varenne,76 1998
at Balloon angioplasty 6 wk Shears,77 1998
ig Balloon angioplasty 3 wk
ig Vein graft 3 wk Kibbe,78 2001
ig Coronary angioplasty 4 wk Wang,79 2001
abbit Balloon angioplasty 2 wk Marks,80 1995
abbit Iliac injury 4 wk Schwarzacher,81 1997
abbit Vein graft 4 wk Chaux,50 1998
abbit Vein graft 4 wk Fulton,82 1998
at Balloon angioplasty 2 wk Kaul,83 2000
ig Coronary angioplasty 8 wk Harnek,84 2003
ig Coronary stent 4 wk Yoon,85 2002
abbit Aortic stent 4 wk Do,86 2004
ig Balloon angioplasty 4 wk Hou,87 2005
oxide synthase; IH, intimal hyperplasia; SPER/NO, spermine/NO; SNAP,l hyp
n S
R
R
R
P
H
M
H
R
R
R
P
R
P
P
P
R
R
R
R
R
P
P
R
Psia after balloon injury of the rat carotid artery.66 Compared
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to-media (I/M) area ratio in rats receiving inhalational NO
for 2 weeks. Rats breathing 80 ppm NO for 7 days showed
no difference in the I/M area ratio. Thus, the entire 14 days
was required to inhibit neointimal hyperplasia. Unfortu-
nately, when Rich et al88 measured the concentration of
NO in the effluent artery of isolated perfused rat lungs
ventilated with NO, they observed that lungs perfused with
whole blood demonstrated undetectable levels of NO due
to the rapid inactivation of NO by hemoglobin. Thus, this
study challenged the study done by Lee et al and suggested
that if adequate levels of NO in the circulation from inha-
lation cannot be achieved, then the differences observed
were not from differences in NO concentrations.
Administration of L-arginine systemically. McNamara
et al67 administered the NO precursor L-arginine to rabbits
from 2 days before to 2 weeks after balloon injury to the
thoracic aorta. Animals receiving L-arginine demonstrated
a 39% decrease in neointimal hyperplasia compared with
the control. This reduction was reversed by coadministra-
tion of the NO inhibitor L-NAME, indicating that these
effects were specific to NO. Subsequently, Chen et al68
administered L-arginine (2.5 mg/mL) in the drinking wa-
ter of rats that underwent balloon injury of the carotid
artery 2 weeks before injury and for 2 weeks thereafter.
Animals treated with L-arginine showed a 65% reduction of
the I/M area ratio and a 26% reduction in the intimal cell
proliferation compared with controls. Despite these suc-
cesses in animal models, no human trials have conclusively
demonstrated the clinical efficacy of systemic L-arginine
administration on inhibiting neointimal hyperplasia.
Administration of nitric oxide donors systemically.
In addition to L-arginine, many studies have also used the
systemic administration of NO donors. Groves et al69 gave
the oral NO donor molsidomine every 8 hours for 48 hours
total in a pig carotid balloon angioplasty model and showed
a 32% reduction in neointimal hyperplasia at 21 days.
However, this was only in circumstances where the internal
elastic lamina remained intact after angioplasty. There was
no significant influence on neointimal hyperplasia in more
severe injury. It is possible that the antiproliferative effects
of orally administered NO were overwhelmed when injury
was severe and, therefore, were not associated with a reduc-
tion in intimal thickening. Despite this fact, Napoli et al71
demonstrated that mice receiving a NO-releasing aspirin
derivative experienced less restenosis after percutaneous
transluminal coronary angioplasty. Unfortunately, admin-
istration of systemic NO has not consistently demonstrated
inhibition of neointimal hyperplasia in human studies.
The Angioplastic Coronaire Corvasal Diltiazem
(ACCORD) study showed that patients undergoing angio-
plasty who received NO from intravenous linsidomine
while an inpatient, followed by oral molsidomine as an
outpatient for a total of 6 months, had a statistically signif-
icant improvement in angiographic results, with a 10%
reduction in luminal diameter.70 In a separate study,
Wohrle et al72 did demonstrate a slight improvement in
anginal status in patients receiving high-dose oral molsido-mine for 6months after coronary angioplasty; however, this
did not translate into an effect on angiographic restenosis
rate. In addition to the conflicting results in human clinical
trials, NO administered systemically can have the undesir-
able effects of vasodilation, hypotension, headaches, and
increased bleeding complications, ultimately limiting its
clinical application.
Nitric oxide synthase gene therapy. Developments
in gene transfer techniques have emerged as an exciting
therapeutic option to treat vascular disease and, as such,
much effort has been invested in studying the effects of
NOS gene transfer on neointimal hyperplasia. In 1995, von
der Leyen73 used a highly efficient Sendai virus/liposome
to transfer eNOS to rat carotid arteries after balloon injury
and demonstrated a 70% reduction in neointimal hyperpla-
sia at 2 weeks. Chen et al74 used a retrovirus to transfect
VSMC with eNOS and used the carotid artery balloon
injury model to demonstrate that neointimal hyperplasia
was inhibited by 37% at 2 weeks after injury. Even in the
larger porcine model, more representative of the human
system, Varenne et al76 found that adenovirus-mediated
transfer of eNOS to VSMC restored NO production in the
injured coronary arteries of pigs and significantly reduced
luminal narrowing.
Gene transfer of iNOS has demonstrated similar effects
on neointimal hyperplasia. Shears et al77 showed that ad-
enoviral delivery of human iNOS to balloon-injured rat
carotid arteries resulted in a 95% reduction in intimal
thickening at 2 weeks. This protective effect was reversed by
continuous infusion of an iNOS-selective inhibitor. In the
more clinically relevant model of the pig iliac artery balloon
injury model, a 52% reduction in the I/M area ratio was
observed after iNOS gene delivery.77 Kibbe et al78 per-
formed iNOS gene transfer in a porcine model of vein
bypass grafting that similarly showed a 30% decrease in the
I/M area ratio at 21 days compared with control. These
results were supported by Wang et al,79 who demonstrated
that iNOS gene transfer inhibits neointimal hyperplasia by
37% in the porcine coronary stent model.
To directly compare adenoviral-mediated overexpres-
sion of both iNOS and eNOS, Cooney et al89 studied
human coronary artery smooth muscle cells and human
umbilical vein endothelial cells infected with adenoviral
vectors encoding eNOS or iNOS. Interestingly, prolifera-
tion was diminished to a similar degree in AdeNOS-
infected and AdiNOS-infected cells compared with nonin-
fected cells in both human coronary artery smooth muscle
cells and human umbilical vein endothelial cells.89 Apopto-
sis was not detected in either cell type with either of the
isoforms. For the first time, these results suggested a similar
effect of both isoforms on endothelial and vascular smooth
muscle cell biology despite the obvious differences between
the NOS isoforms.
Local application of nitric oxide donors. Many in-
vestigators have studied the effects of locally delivered NO
on sites of arterial injury. Marks et al80 investigated the
impact of a polythiolated form of bovine serum albumin
(pS-BSA) modified to carry several S-nitrosothiol groups
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delivered pS-NO-BSA reduced the development of neoin-
timal hyperplasia by 77% and also inhibited platelet depo-
sition after denudation of the artery. Furthermore, Schwar-
zacher et al81 showed at 4 weeks after balloon injury that
delivery of intramural L-arginine in rabbits enhanced local
NO generation and inhibited neointimal hyperplasia by
37%. Vein grafts treated with L-arginine polymer were also
demonstrated by Kown et al90 to increase NO levels and
reduce neointimal hyperplasia in a rabbit vein graft model.
Other NO-donors such as SPER/NO, when locally
applied, have also shown inhibition of neointimal hyperpla-
sia: 41% in rabbit vein graft models after 4 weeks and 73% in
rat balloon angioplasty models after 2 weeks.50,83 Further-
more, inhibition of neointimal hyperplasia has been ob-
served by other locally delivered NO donors, such as mol-
sidomine on a hydrogel-coated angioplasty balloon
catheter in pigs, SNAP gel on rabbit vein grafts, and 3-
morpholino-sydnonimine after pig percutaneous translu-
minal coronary angioplasty.91,82,84
Prosthetic materials that release nitric oxide. Each
of the mentioned therapies have some limitations in their
clinical applicability because of systemic side effects, safety
concerns, complicated delivery schemes, or inability to
concentrate NO at the site of injury for prolonged periods
of time. To circumvent these problems, recent research has
been directed at administering NO through NO-releasing
prosthetic materials. In fact, NO-releasing prosthetic ma-
terials gained widespread attention recently in The New
England Journal of Medicine.92
As early as 2002, Yoon et al85 used the NO donor
sodium nitroprusside incorporated into a metallic coil stent
coated with a polyurethane polymer to investigate the
effect on neointimal hyperplasia in the porcine coronary
artery stent injury model. The stented arteries did release
increased NO and demonstrated increased local cGMP
levels, but no difference in neointimal area was observed
between control and treatment groups after 4 weeks.88
Two subsequent studies by Hou et al87 and Do et al86 did
demonstrate a reduction in neointimal hyperplasia with
application of a NO-eluting stent. In 2004, Do et al de-
ployed stents containing bioerodablemicrospheres of theNO
donor N-ethyl-2-(1-ethyl-2-hydroxy-2-nitrosohydrazino)
ethanamine into the aortas of rabbits. Nitric oxide release
was sustained for 3 weeks, and the I/M area ratio in the
NO-treated group was reduced by 46% and 32% relative to
controls at 7 and 28 days, respectively.
One year later, Hou et al also demonstrated a reduction
in neointimal proliferation when they used silicone-
containing sodium nitroprusside to coat the interior of a
self-expanding polytetrafluoroethylene-covered stent. Af-
ter implanting the stent and inducing balloon overstretch
injury to the pig carotid artery, the mean neointimal area
was reduced from 2.4 mm2 for control stents to 0.49 mm2
for NO-eluting stents, which resulted in a 24% reduction of
angiographic vessel narrowing. These studies demonstrate
the importance of the NO donor used as well as the
polymer.Several investigators have recently used NO-releasing
molecules to modify prosthetic bypass grafts. Because this
research is in its infancy, focus has been more on the
biomechanics of NO release and the effect of these alter-
ations on the prosthetic materials. Smith et al93 were the
first to use diazeniumdiolates in polymers and incorporate
those polymers into vascular grafts. These grafts did spon-
taneously release NO. Unfortunately, the coating process
changed the architecture of the graft, which potentially
limited the long-term biocompatibility of the technique.
Another method developed by Zhang et al94 incorpo-
rated diazeniumdiolated silica nanoparticles into vascular
grafts by embedding them into hydrophobic matrices that
were then used to coat the inside lining of extracorporeal
venovenous circuits in the rabbit model. Unfortunately, the
diazeniumdiolates used in these studies demonstrated
leaching, and measurable levels of nitrosamines, a well-
known class of carcinogens, were formed. To address this
issue, investigators have attempted techniques such as coat-
ing grafts with layers of a diazeniumdiolate-containing
polyvinyl chloride or covalently binding diazeniumdiolates
into a polyurethane backbone to prevent leaching and
further optimize the properties of the NO-releasing pros-
thetic materials.95-97
The S-nitrosothiols are another class of NOdonors that
have been used in the development of NO-releasing poly-
mers. Several polymers have been developed with the S-
nitrosothiol covalently linked to the polymer to prevent
leaching or reaction by-products. Bohl and West98 used
S-nitrosothiols to create a NO-releasing hydrogel, specu-
lating that this material could be used to coat the vessel wall
or vascular grafts. Unfortunately, the limitation of using
both diazeniumdiolates and S-nitrosothiols is the finite
reservoir of NO available. New materials are being devel-
oped that rely on S-nitrosothiols or nitrite, or both, that is
already circulating in the blood as an unlimited endoge-
nous source of NO.99,100 Once the biomechanics of these
NO-releasing prosthetic materials are perfected, attention
can then be turned to their influence on neointimal hyper-
plasia.
CONCLUSION
Nitric oxide-based therapies have tremendous potential
to have a significant impact on the development of neoin-
timal hyperplasia in the clinical arena. Here we describe the
basics of NO, the arterial injury response, and the patho-
physiologic role of NO in the development of neointimal
hyperplasia, and lastly the clinical applications of NO-based
therapies. Overall, we believe that NO-based pharmaco-
logic approaches tailored to locally deliver a set concentra-
tion of NO over a specific period of time will prove to be a
valuable therapy in vascular surgery.
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